Dechra Veterinary Products is pleased to announce its exclusive marketing, sales and distribution agreement with Kindred Biosciences. Dechra has licensed the long-term distribution rights for Zimeta® (dipyrone injection), which will further bolster Dechra’s equine product portfolio.
Zimeta is the first and only FDA-approved drug for the control of pyrexia in horses.
When administered according to label directions, Zimeta, an intravenous, non-steroidal anti-inflammatory injection, demonstrates rapid and effective control of fever in horses in clinical studies. Dipyrone, the active ingredient in Zimeta, is a member of the pyrazolone class of non-steroidal anti-inflammatory drugs (NSAIDs) and has a centrally acting mechanism of action on the hypothalamus where fever originates and is regulated.
Zimeta is the latest addition to Dechra’s equine portfolio, which includes OSPHOS® (clodronate injection), Orthokine® Vet irap, Osteokine® (PRP), Equidone® (domperidone), Vetivex® Fluid Therapy, and Phycox® EQ joint health supplements.
Mike Eldred, President of North American Operations, commented: “We are pleased to have partnered with Kindred Biosciences to add Zimeta to our equine product lines in the US and Canada. Dechra’s Equine sales team is excited to launch Zimeta and provide veterinarians with a novel product to help control fevers in horses.”
The product is now available for veterinarians to purchase through select veterinary distributors.
